REGENXBIO Inc. (RGNX): A Bull Case Theory [Yahoo! Finance]
REGENXBIO Inc. (RGNX)
Last regenxbio inc. earnings: 2/26 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.regenxbio.com
Company Research
Source: Yahoo! Finance
REGENXBIO Inc.'s share was trading at $13.76 as of January 15th. Pressmaster/Shutterstock.com REGENXBIO is a clinical-stage biotechnology company focused on the development of gene therapies built on its proprietary NAV Technology platform, leveraging AAV8 and AAV9 vectors. Its lead program, surabgene lomparvovec (sura-vec, ABBV-RGX-314), partnered with AbbVie, targets wet age-related macular degeneration and diabetic retinopathy by enabling sustained intraocular production of an anti-VEGF antibody fragment, significantly reducing the need for repeated injections. This is the largest retinal gene therapy program to date, with more than 1,200 patients enrolled across the ATMOSPHERE and ASCENT pivotal trials. Beyond ophthalmology, REGENXBIO is advancing RGX-202 for Duchenne muscular dystrophy, differentiated by a microdystrophin construct with a C-terminal domain aimed at improving functional outcomes, and RGX-121 for MPS II, which has demonstrated an 82% median reduction in a key
Show less
Read more
Impact Snapshot
Event Time:
RGNX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RGNX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RGNX alerts
High impacting REGENXBIO Inc. news events
Weekly update
A roundup of the hottest topics
RGNX
News
- REGENXBIO Highlights Key 2026 Catalysts and Announces Positive Long-Term Functional Outcomes in Lead Duchenne Gene Therapy Program [Yahoo! Finance]Yahoo! Finance
- REGENXBIO Highlights Key 2026 Catalysts and Announces Positive Long-Term Functional Outcomes in Lead Duchenne Gene Therapy ProgramPR Newswire
- REGENXBIO (NASDAQ:RGNX) was given a new $45.00 price target on by analysts at Stifel Nicolaus.MarketBeat
- REGENXBIO to Present at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- REGENXBIO to Present at the 44th Annual J.P. Morgan Healthcare ConferencePR Newswire
RGNX
Earnings
- 11/6/25 - Beat
RGNX
Sec Filings
- 1/8/26 - Form 4
- 1/8/26 - Form 4
- 1/8/26 - Form 4
- RGNX's page on the SEC website